Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Probi AB (publ)
  6. News
  7. Summary
    PROB   SE0001280355


Delayed Quote. Delayed Nasdaq Stockholm - 07/29 11:29:55 am
499 SEK   +3.10%
07/16Probi Seeks Acquisitions
07/16Q2 2021 : Probi enters new strategic partnerships
07/16Probi AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Probi : and China National Pharmaceutical Foreign Trade Corporation have signed a License & Supply Agreement

04/22/2021 | 08:02am EDT

This press release was originally released on 29th March 2021. The correct, full name of China National Pharmaceutical Foreign Trade Corporation and changes to the company description and quotes are hereby updated.

The Swedish probiotic supplier, Probi® and China National Pharmaceutical Foreign Trade Corporation (SINOPHARM FORIGN TRADE), a wholly-owned subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM), has entered a partnership to expand the offering of premium probiotic offerings in the Chinese market on Feb 5th, 2021.

SINOPHARM FORIGN TRADE will launch three probiotic supplements within the three aspects of immune health, bone health and iron absorption based on Probi's scientifically proven probiotic strains.

Zhang Jiange, Director Pharmaceutical & Chemical Division of SINOPHARM FORIGN TRADE, states: "SINOPHARM FORIGN TRADE continues to commit to our strong sense of social responsibility guided by our core value "All for health, Health for all" and the important partnership with Probi, especially its first-class R&D capability helps us contribute with positive impact to China's consumer healthcare industry."

And she continues: "These probiotics strains have relevant scientific verification and will be introduced under a new brand to expand SINOPHARM FORIGN TRADE's existing supplement portfolio."

Probiotics are a high-growth segment in China with a CAGR of 10.3% in the next 5 years according to Euromonitor.

Veronica Dong, Head of APAC, Probi: "We are excited to be partner with SINOPHARM FORIGN TRADE, who shares our vision of bringing innovative and scientifically supported products into China and the APAC region. With this partnership Probi has demonstrated its position as a leading probiotic company to capture high growth markets in the region such as China."

"The partnership between Probi and SINOPHARM FORIGN TRADE is an important step in our commercial efforts in offering clinically documented probiotic products to consumers all over the world, and our expansion into China is a good step forward in establishing Probi's position in the APAC region. In our partnership with SINOPHARM FORIGN TRADE we feel commitment and alignment in offering high quality products based upon research, clinical documentation and performance," says Tom Rönnlund, CEO, Probi.

For further information, please contact:

Tom Rönnlund, CEO, Probi®,
Phone: +46 46 286 89 40, E-mail: trd@probi.com
Veronica Dong, Head of APAC, Probi®Phone: +65 6439 2313,
E-mail: veronica.dong@probi.comCharlotte Beyerholm, Director Marketing & Global Communication, Probi®,
Phone: +46 76 870 94 65, E-mail: charlotte.beyerholm@probi.com


Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi® has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com.

Probi® is a registered trademark of Probi AB.

ABOUT China National Pharmaceutical Foreign Trade Corporation

Established in 1981, China National Pharmaceutical Foreign Trade Corporation (SINOPHARM FOREIGN TRADE) is a wholly-owned subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM), a leading medical and healthcare group in China. SINOPHARM FOREIGN TRADE is committed to international trade of pharmaceutical products and medical industrial investment. It has established integrated multiple business models and diversified business sectors including international business of medical and health products, procurement services for medical institutions, discipline development services in medical institutions, and pharmaceutical supply chain service, which has established high reputation in the industry and accumulated rich and high-quality medical resources on a global scale.  Read more at www.sino-pharm.com




(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 3.10% 499 Delayed Quote.18.25%
SYMRISE AG -0.65% 122.65 Delayed Quote.13.15%
All news about PROBI AB (PUBL)
07/16Probi Seeks Acquisitions
07/16Q2 2021 : Probi enters new strategic partnerships
07/16Probi AB Publ Reports Earnings Results for the Second Quarter Ended June 30, ..
07/13PROBI : Presentation of Probi's Q2 report 2021
07/13PROBI : Presentation of Probi's Q2 report 2021
07/06PROBI : Snaps Up 13% Stake In Blis Technologies For $6 Million
07/06PROBI : acquires newly issued shares in New Zealand's Blis...
07/06Probi acquires newly issued shares in New Zealand's Blis Technologies and ent..
07/06Blis Technologies and Probi AB Signs a Licensing and Distribution Agreement
06/15PROBI : and Oriflame enter partnership for digestive...
More news
Sales 2021 712 M 83,2 M 83,2 M
Net income 2021 95,0 M 11,1 M 11,1 M
Net cash 2021 251 M 29,3 M 29,3 M
P/E ratio 2021 59,6x
Yield 2021 0,24%
Capitalization 5 686 M 665 M 664 M
EV / Sales 2021 7,63x
EV / Sales 2022 6,34x
Nbr of Employees -
Free-Float 36,6%
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts 2
Last Close Price 499,00 SEK
Average target price 505,00 SEK
Spread / Average Target 1,20%
EPS Revisions
Managers and Directors
Tom Juhani R÷nnlund Chief Executive Officer
Henrik Lundkvist Chief Financial Officer
Jean-Yves Parisot Chairman
Niklas Brandt Vice President-Information Technology
Niklas Larsson Lead Scientific Affairs
Sector and Competitors
1st jan.Capi. (M$)
PROBI AB (PUBL)18.25%665
NESTLÉ S.A.9.46%343 525
DANONE13.21%43 928